Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUBRAMANYESWARA R AREKAPUDI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366671943
CMS profile
16469
Location
RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$7,021.57

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,132.00 2
Food and Beverage $1,514.64 57
Education $374.93 4

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUBRAMANYESWARA R AREKAPUDI

NPI 1366671943 · CMS profile ID 16469

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366671943?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUBRAMANYESWARA R AREKAPUDI, NPI 1366671943, CMS profile ID 16469. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366671943?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SUBRAMANYESWARA R AREKAPUDI, NPI 1366671943, CMS profile ID 16469. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366671943?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SUBRAMANYESWARA R AREKAPUDI, NPI 1366671943, CMS profile ID 16469, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1366671943?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $7,021.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–63 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $99.9505/04/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943039959 CMS
G1 Therapeutics, Inc. $13.5605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954026985 CMS
Seagen Inc. $22.9104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904083711 CMS
Ipsen Biopharmaceuticals, Inc $15.8004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893392001 CMS
PFIZER INC. $19.4504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949350359 CMS
EMD Serono, Inc. $13.3604/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941506519 CMS
BeiGene USA, Inc. $113.9704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940791385 CMS
Organon LLC $12.8204/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946432013 CMS
GlaxoSmithKline, LLC. $32.1104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944843279 CMS
Regeneron Healthcare Solutions, Inc. $30.6204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927100245 CMS
E.R. Squibb & Sons, L.L.C. $2,372.0003/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932651247 CMS
Astellas Pharma US Inc $79.9902/01/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940112675 CMS
GlaxoSmithKline, LLC. $24.6101/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944843277 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49.36 3
PY2020 $313.80 14
PY2021 $2,616.27 42
PY2022 $7,021.57 63
PY2023 $22,947.94 96
PY2024 $1,120.67 46
PY2025 $884.03 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $128,966.67 12
PY2023 Principal investigator $49,840.00 5
PY2022 Principal investigator $34,823.00 2
PY2021 Principal investigator $26,950.00 7
PY2020 Principal investigator $56,941.82 3
PY2019 Principal investigator $42,074.37 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PharmaEssentia USA Corporation $1,370.00 08/28/2024 Non-covered Recipient Entity
Cancer Care Specialists
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137324341
Principal investigator 1 ADC Therapeutics America, Inc. $88.79 05/29/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126521008
Principal investigator 1 ADC Therapeutics America, Inc. $1,500.00 05/23/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126521002
Principal investigator 1 PharmaEssentia USA Corporation $4,801.83 04/26/2024 Non-covered Recipient Entity
Cancer Care Specialists
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137324337
Principal investigator 1 Karyopharm Therapeutics Inc. $1,750.00 04/15/2024 Non-covered Recipient Entity
Cancer Care Specialists
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1145531289
Principal investigator 1 ADC Therapeutics America, Inc. $26,188.11 03/12/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126520918
Principal investigator 1 AstraZeneca UK Limited $72,523.54 02/01/2024 Non-covered Recipient Entity
CANCER CARE SPECIALISTS
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1110842311
Principal investigator 1 Celgene Corporation $4,900.00 01/31/2024 Non-covered Recipient Entity
John A. Shields MD & Steven A. Schiff MD Dba Cance
The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1120432964
Principal investigator 1 ADC Therapeutics America, Inc. $100.00 01/25/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126520920
Principal investigator 1 ADC Therapeutics America, Inc. $9,166.30 01/25/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126520926
Principal investigator 1 ADC Therapeutics America, Inc. $300.00 01/16/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126520922
Principal investigator 1 ADC Therapeutics America, Inc. $6,278.10 01/16/2024 Non-covered Recipient Entity
JOHN A SHIELDS MD AND STEVEN A SCHIFF MD A PROFFESSIONAL CORPORATION
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 1126520924